| Property | Value |
|---|
|
?:abstract
|
-
Introduction Tube-related adverse events (AEs) occur frequently in patients with Parkinson’s disease (PD) receiving levodopa-carbidopa intestinal gel therapy Endoscopy has become evasive since the beginning of the coronavirus disease 2019 (COVID-19) pandemic This study aimed to evaluate methods that use the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tubes without endoscopy Methods We included 19 patients in this study The contrast agent was injected into the PEG-J tube to clarify the AEs related to the use of the tube When the kink of the PEG-J tube was found, it was pulled approximately 5–10 cm When placing or replacing the PEG-J tube, the percutaneous endoscopic gastrostomy (PEG) tube was pushed into the gastrostomy hole to bring its tip closer to the pylorus before a new PEG-J tube was inserted into it Results The mean patient age was 63 1 ± 9 9 years, while the mean duration of PD was 16 7 ± 6 3 years Tube-related AEs included PEG-J tube kinks (32 events), connector failures (20 events), and PEG-J tube entanglements without/with bezoars (9 events/5 events) All PEG-J tube kinks were resolved by tube manipulation with a fluoroscopic guide In 66 of 85 events (77 6%), the PEG-J tube was placed or replaced without endoscopy We believe that the use of the antispasmodic agent just before PEG-J operation reduced this rate Conclusion Our methods were able to resolve most AEs associated with PEG-J tube use without endoscopy
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Clinical_Parkinsonism_&_Related_Disorders
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}